Dr. Matt Vincent is the Chief Business Officer for AdvanCell Isotopes, a clinical stage next generation targeted alpha therapy (TAT) radiopharmaceutical company.  Prior to joining AdvanCell, Dr. Vincent led the business development team at another radiopharmaceutical company, POINT Biopharma, including through the acquisition of that company by Eli Lilly.  Matt is based in Boston and has over 30 years of experience in innovation, drug development, business development and M&A strategy. He has also contributed to therapeutic discovery – including as an inventor on several pipeline programs in different companies and is a scientific co-founder of AsymmetRx (prostate cancer biopsy assay), CodeBridgeBio (room temperature stable LNPs), FerRxBio (treatments for AMD), IOzyme (precision I/O agents) and Tract Pharmaceuticals (targeting stem cells underlying inflammatory diseases). Dr. Vincent’s scientific publications include papers in the Lancet, Nature, Cell and Gastroenterology, amongst others.